Ultrasound Enhances Noninvasive Down Syndrome Tests
|
By MedImaging International staff writers Posted on 21 Dec 2009 |
The addition of a "genetic sonogram” maximizes the accuracy of noninvasive testing for Down syndrome.
"We wanted to be able to definitively describe the detection and accuracy of noninvasive prenatal screening for the detection of Down syndrome,” said Dr. Kjersti Aagaard, assistant professor of obstetrics and gynecology at Baylor College of Medicine (BCM; Houston, TX, USA) and the lead author of the landmark study, published in the November 2009 issue of the journal Obstetrics and Gynecology. "Using our data generated in the most comprehensive study performed to date (FaSTER [for First and Second Trimester Evaluation of Risk] trial), we demonstrated that the addition of a genetic sonogram to all modes of screening in pregnancy allows for optimal noninvasive prenatal detection of Down syndrome.”
Noninvasive screening for Down syndrome (as well as the other major fetal genetic or chromosomal abnormalities in the developing infant) involves a specific early ultrasound and series of tests for biochemical components in the mother's blood at specific times during pregnancy. Depending on the institution and clinic, tests are performed during the first and/or second trimesters of pregnancy. Optimally, noninvasive screening also includes that a preliminary ultrasound to detect nuchal translucency takes place late in the first trimester. The test measures the clear or translucent space in the tissue at the back of the fetus' neck. If there is an abnormality, fluid will accumulate in the back of the neck, making the nuchal fold area larger.
In the first trimester, measured maternal serum markers include pregnancy-associated plasma protein A (PAPP-A) and free beta human chorionic gonadotropin (beta hCG). In the second trimester, physicians measure alpha-fetoprotein, beta hCG, unconjugated estriol and inhibin A. The tests ordered and the combinations vary among institutions and clinics. Often, these tests are utilized as a basis for counseling women on the option of the more invasive but definitive tests such as amniocentesis, which involves directly measuring the chromosomal material in fetal cells found in the fluid inside the uterus, and chorionic villus sampling, an earlier means of obtaining fetal cells from tissue found in the placenta. Each is the definitive means of testing for genetic or chromosomal disorders that affect the fetus.
However, each of these invasive tests carries risk for potential complications, and many pregnant women seek to avoid those risks if at all possible. Because of this, researchers have spent several decades optimizing noninvasive prenatal diagnostic screening. One key component of this screening program has come to include the genetic sonogram. A genetic sonogram is simply an advanced ultrasound that details the fetal anatomy in the second trimester, looking for the presence of major fetal anomalies or specific anatomic features (so-called "soft markers") that might be found in a child with Down syndrome, according to Dr. Aagaard.
"Because we build off of the FaSTER trial, our reported adjusted risk measures we describe in this manuscript serve as definitive evidence that the sonogram improves the sensitivity of detection [making it less likely that a Down syndrome diagnosis would be missed] and also decreases the false positive rate,” said Dr. Aagaard. "Combining this with first or first and second trimester screening for biochemical markers gives us the maximal capacity to detect Down syndrome in a noninvasive fashion.”
Dr. Aagaard and her colleagues screened over 8,000 of the nearly 39,000 pregnant women who took part in the FaSTER trial of screening for chromosomal abnormalities (aneuploidy). The detection rate of Down syndrome babies varied from 69% for the genetic sonogram alone to as high as 98% with certain combinations of the biochemical markers. More importantly, the improved detection rate was accompanied by a decrease in the screening tests false-positive rates (or falsely reported risk of Down syndrome in a normal pregnancy).
Related Links:
Baylor College of Medicine
"We wanted to be able to definitively describe the detection and accuracy of noninvasive prenatal screening for the detection of Down syndrome,” said Dr. Kjersti Aagaard, assistant professor of obstetrics and gynecology at Baylor College of Medicine (BCM; Houston, TX, USA) and the lead author of the landmark study, published in the November 2009 issue of the journal Obstetrics and Gynecology. "Using our data generated in the most comprehensive study performed to date (FaSTER [for First and Second Trimester Evaluation of Risk] trial), we demonstrated that the addition of a genetic sonogram to all modes of screening in pregnancy allows for optimal noninvasive prenatal detection of Down syndrome.”
Noninvasive screening for Down syndrome (as well as the other major fetal genetic or chromosomal abnormalities in the developing infant) involves a specific early ultrasound and series of tests for biochemical components in the mother's blood at specific times during pregnancy. Depending on the institution and clinic, tests are performed during the first and/or second trimesters of pregnancy. Optimally, noninvasive screening also includes that a preliminary ultrasound to detect nuchal translucency takes place late in the first trimester. The test measures the clear or translucent space in the tissue at the back of the fetus' neck. If there is an abnormality, fluid will accumulate in the back of the neck, making the nuchal fold area larger.
In the first trimester, measured maternal serum markers include pregnancy-associated plasma protein A (PAPP-A) and free beta human chorionic gonadotropin (beta hCG). In the second trimester, physicians measure alpha-fetoprotein, beta hCG, unconjugated estriol and inhibin A. The tests ordered and the combinations vary among institutions and clinics. Often, these tests are utilized as a basis for counseling women on the option of the more invasive but definitive tests such as amniocentesis, which involves directly measuring the chromosomal material in fetal cells found in the fluid inside the uterus, and chorionic villus sampling, an earlier means of obtaining fetal cells from tissue found in the placenta. Each is the definitive means of testing for genetic or chromosomal disorders that affect the fetus.
However, each of these invasive tests carries risk for potential complications, and many pregnant women seek to avoid those risks if at all possible. Because of this, researchers have spent several decades optimizing noninvasive prenatal diagnostic screening. One key component of this screening program has come to include the genetic sonogram. A genetic sonogram is simply an advanced ultrasound that details the fetal anatomy in the second trimester, looking for the presence of major fetal anomalies or specific anatomic features (so-called "soft markers") that might be found in a child with Down syndrome, according to Dr. Aagaard.
"Because we build off of the FaSTER trial, our reported adjusted risk measures we describe in this manuscript serve as definitive evidence that the sonogram improves the sensitivity of detection [making it less likely that a Down syndrome diagnosis would be missed] and also decreases the false positive rate,” said Dr. Aagaard. "Combining this with first or first and second trimester screening for biochemical markers gives us the maximal capacity to detect Down syndrome in a noninvasive fashion.”
Dr. Aagaard and her colleagues screened over 8,000 of the nearly 39,000 pregnant women who took part in the FaSTER trial of screening for chromosomal abnormalities (aneuploidy). The detection rate of Down syndrome babies varied from 69% for the genetic sonogram alone to as high as 98% with certain combinations of the biochemical markers. More importantly, the improved detection rate was accompanied by a decrease in the screening tests false-positive rates (or falsely reported risk of Down syndrome in a normal pregnancy).
Related Links:
Baylor College of Medicine
Latest Ultrasound News
- AI Robotic Ultrasound System Automates Echocardiography and Improves Consistency
- Whole Cross-Section Ultrasound System Enables Operator-Independent Imaging
- New Ultrasound AI Tool Supports Rapid Prenatal Assessment
- New Consensus Standardizes Ultrasound-Based Fatty Liver Assessment
- Groundbreaking Technology to Enhance Precision in Emergency and Critical Care
- Reusable Gel Pad Made from Tamarind Seed Could Transform Ultrasound Examinations
- AI Model Accurately Detects Placenta Accreta in Pregnancy Before Delivery
- Portable Ultrasound Sensor to Enable Earlier Breast Cancer Detection
- Portable Imaging Scanner to Diagnose Lymphatic Disease in Real Time
- Imaging Technique Generates Simultaneous 3D Color Images of Soft-Tissue Structure and Vasculature
- Wearable Ultrasound Imaging System to Enable Real-Time Disease Monitoring
- Ultrasound Technique Visualizes Deep Blood Vessels in 3D Without Contrast Agents
- Ultrasound Probe Images Entire Organ in 4D

- Disposable Ultrasound Patch Performs Better Than Existing Devices
- Non-Invasive Ultrasound-Based Tool Accurately Detects Infant Meningitis
- Breakthrough Deep Learning Model Enhances Handheld 3D Medical Imaging
Channels
Radiography
view channel
Rapid X-Ray Test Quantifies Pulmonary Regurgitation After Tetralogy of Fallot Repair
Tetralogy of Fallot is the most common cyanotic congenital heart defect and can leave patients with pulmonary valve regurgitation, a backward flow of blood into the right ventricle after repair.... Read more
AI Tool Flags Osteoporosis Risk from Routine Chest X-Rays
Osteoporosis is a progressive loss of bone density that is often silent until a fracture occurs. Current screening frameworks concentrate on older women and select high-risk groups. Many men, younger adults,... Read moreMRI
view channel
AI Approach Could Shorten Advanced Brain MRI Scans by Up to 90%
Long acquisition times for advanced brain magnetic resonance imaging (MRI) can limit access, extend waiting lists, and disrupt clinical workflows. Reducing data requirements without sacrificing image fidelity... Read more
Cardiac MRI Measure Improves Risk Prediction in Tricuspid Regurgitation
Tricuspid regurgitation, in which blood flows back from the right ventricle into the right atrium, can lead to progressive right-sided heart failure. Clinicians need reliable ways to gauge severity and... Read moreNuclear Medicine
view channel
Targeted PET Platform Guides Osteosarcoma Resection and Margin Verification
Osteosarcoma, an aggressive primary bone cancer that mainly affects children and adolescents, demands wide excision to prevent local recurrence. Surgeons must achieve negative margins while preserving... Read more
Portable PET System Enables Real-Time Bedside Guidance for Biopsies and Ablations
Interventional radiology procedures typically rely on ultrasound, X-ray fluoroscopy, or computed tomography for image guidance. These modalities visualize anatomy but offer limited molecular information,... Read moreGeneral/Advanced Imaging
view channelNew SPECT/CT Method Differentiates Inflammation from Fibrosis in Interstitial Lung Disease
Interstitial lung disease (ILD) encompasses more than 200 disorders that inflame or scar the lung interstitium and can lead to progressive respiratory failure. Determining whether active inflammation is... Read more
Whole-Body PET/CT Tracks Metabolic Changes After Bariatric Surgery
Obesity surgery improves weight and comorbidity profiles, yet clinicians lack tools to monitor organ-level metabolic recovery after the procedure. A clear view of systemic changes could refine follow-up... Read moreImaging IT
view channel
Interactive AI Tool Supports Explainable Lung Nodule Assessment
Lung cancer is a leading cause of cancer mortality, and timely characterization of pulmonary nodules on chest computed tomography (CT) is essential for directing care. Interpreting nodule morphology demands... Read more
Breast Imaging Software Enhances Visualization and Tissue Characterization in Challenging Cases
Breast imaging can be particularly challenging in cases involving small breasts or implants, where image reconstruction and tissue characterization may be limited. Clinicians also need reproducible analysis... Read more
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology
The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read moreIndustry News
view channel
GE HealthCare Showcases AI-Enabled Nuclear Medicine Portfolio at SNMMI 2026
Nuclear medicine is expanding rapidly as health systems adopt theranostics and broaden access to radiopharmaceuticals, increasing demand for scalable operations and consistent diagnostic confidence.... Read more
GE HealthCare Highlights AI-Supported Radiation Therapy Tools at ESTRO 2026
At the European Society for Radiotherapy and Oncology (ESTRO) 2026 Congress in Stockholm, GE HealthCare is highlighting Intelligent Radiation Therapy (iRT), MIM Software innovations, and BK Medical surgical... Read more







